Dogwood Therapeutics (NASDAQ:DWTX) Trading 4.3% Higher – Here’s Why

Dogwood Therapeutics, Inc (NASDAQ:DWTX) traded up 4.3% on Monday . The company traded as high as $1.74 and last traded at $1.71. Approximately 83,119 shares changed hands during mid-day trading, an increase of 21% from the average session volume of 68,704 shares. The stock had previously closed at $1.64.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DWTX shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Tuesday, May 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Dogwood Therapeutics currently has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Performance

The stock has a market capitalization of $61.54 million, a PE ratio of -0.17 and a beta of 1.71. The company’s fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $2.09.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Sell-side analysts forecast that Dogwood Therapeutics, Inc will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.